Spare a thought for your Scandinavian colleagues who are running CROs
Spare a thought for your Scandinavian colleagues who are running CROs: staff turnover among companies in Norway was 47% in 2015, and the comparable figure for Denmark was 43%, according to the 18th annual CRO Industry Global Compensation and Turnover Survey conducted by HR+Survey Solutions, LLC.
More than half of the countries surveyed (24 of the 45) had average turnover of 20% or more. Others with high turnover rates were India (36%), New Zealand (33%), and Switzerland (30%), Taiwan (29%), Finland (28%), and China (28%).
In the U.S., overall staff turnover increased slightly to 20.1% in 2015 from 19.5% in 2014 for all positions in CROs. Turnover in the U.S. for clinical monitoring jobs at CROs remained high at 25.1% in 2015, compared with 25.4% in 2014, 16.4% in 2013, 24.4% in 2012, and 29.4% in 2011.
U.S. unemployment has continued to decline since it peaked in 2009, and currently is well below 5%. This means that CROs have an uphill battle identifying new talent sources.
“Turnover is a significant business issue; high turnover can undermine the relationship with a sponsor,” noted Judy Canavan, managing partner of HR+Survey Solutions and the author of the study. “Employees have figured out that changing jobs is the key to maximizing their compensation and rounding out their CV, companies need to create internal career opportunities.”
According to Canavan, the number of registered clinical trials has risen sharply from 24,921 in 2005 to 231,508 as of December 4, 2016 (source: http://clinicaltrials.gov/ct2/resources/trends).
Other findings of the survey were:
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.